Now I have a thorough understanding of the paper, the harsh critic's points, the strength finder's input, and the calibration anchors. Let me write the final consolidated review.

---

## Summary

This paper introduces a conformal prediction procedure for counterfactual survival outcomes under general right-censoring. The key contribution is a reweighting scheme that transforms the counterfactual coverage problem into a weighted conformal inference task, yielding exact finite-sample marginal coverage guarantees (not just PAC-type). The method is accompanied by non-asymptotic bounds on coverage loss due to weight estimation error and a doubly robust asymptotic property. Synthetic experiments across six configurations validate coverage and informativeness advantages over PAC-type baselines; a real NSCLC clinical dataset illustrates the method's applicability.

## Strengths

- **Exact coverage guarantee for counterfactual survival prediction:** The paper is the first to provide exact (not PAC-type) marginal coverage for LPBs of counterfactual survival times under general right-censoring. The derivation transforms the coverage probability into a weighted expectation (Section 4.1, equation 1), enabling a weighted conformal calibration procedure. Synthetic experiments (Figure 1) confirm coverage rates near the nominal 90% across all six settings.

- **Doubly robust theoretical property:** Theorem 4.2 proves that asymptotic coverage holds if either the weight function or the counterfactual quantile regression model is consistently estimated. This is an unusual and valuable result in the conformal prediction literature, adding theoretical depth beyond standard coverage guarantees. Sensitivity experiments in Appendices E.4 and E.5 support this property by showing maintained coverage under different regressors and weight estimators.

- **Superior empirical informativeness and robustness on synthetic data:** Across six synthetic configurations with varying censoring and treatment rates, the proposed LPB is consistently less conservative than naive, focused, and fused baselines while staying close to target coverage (Figure 1). In outlier-contaminated scenarios, the method uniquely retains valid coverage while PAC-type baselines fail (Figure 3), validating the practical value of exact over PAC guarantees.

- **Clinically meaningful adaptiveness:** The LPB varies coherently with known prognostic factors (stage, KPS, tumor size) on the real NSCLC dataset (Figure 5), demonstrating that the bounds are informative for personalized treatment assessment, not merely vacuous guarantees.

- **LPB optimization:** The procedure for selecting τ to maximize LPB while preserving coverage (Section 4.1, Table 1) yields tangible gains in bound tightness without sacrificing validity.

## Weaknesses

### Fatal

None.

### Major

- **Real-data evaluation implicitly overstates what can be validated:** The coverage rates on the clinical dataset (Section 5.2) can only be assessed for the treatment each patient *actually* received — counterfactual outcomes are, by definition, unobserved. While the synthetic experiments do validate counterfactual coverage, the real-data results are presented in a way that could mislead readers into thinking counterfactual coverage has been empirically verified on clinical data. The cross-treatment LPB comparisons (e.g., VMAT vs. IMRT) are interpreted as treatment effect evidence (lines 845–852) but rely entirely on untestable ignorability assumptions. The paper would be substantially stronger if it explicitly separated (a) what the real-data analysis validates (factual survival prediction under a chosen treatment) from (b) what it merely illustrates under strong assumptions (counterfactual comparisons). The discussion (lines 890–893) acknowledges the difficulty of satisfying assumptions in practice but does not engage with the specific confounding structure of the lung cancer cohort or clearly delineate these limits for readers.

### Minor

- **No sensitivity analysis for ignorability violations:** While the Discussion (line 891) acknowledges that Assumption 3.1 is hard to guarantee in practice, there is no empirical exploration — even in the synthetic setup — of how violations of ignorability (e.g., unmeasured confounding or informative censoring) degrade coverage. The synthetic experiments could easily be extended to introduce such violations, which would give readers a more honest picture of the method's reliability under realistic conditions. This matters because the method's practical utility in clinical settings depends crucially on this assumption.

- **Cross-treatment comparisons on real data lack caveats:** The real-data results (lines 847–852) compare LPBs across treatments and interpret higher LPBs as evidence of treatment superiority, citing external clinical literature for validation. While the correlations with clinical findings are noted as "consistent with," the text does not sufficiently caution that these comparisons assume full ignorability and could reflect confounding rather than genuine treatment effects. A sentence or two explicitly flagging this would improve scientific rigor.

### Trivial

- The caption for Figure 4 (lines 812–817) appears misplaced in the parsed text, preceding rather than following the figure it describes, making it hard to parse which results belong to which section. This is likely a parser artifact but worth checking in the original submission.

## Nice-to-Haves

- Extending the synthetic setup to introduce unmeasured confounding or informative censoring would allow readers to assess how the method degrades under assumption violations — a valuable addition for a method targeting clinical applications.
- Extension to multiple treatments beyond binary with a unified calibration procedure would broaden practical relevance, as the authors note in the discussion.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **Harsh Critic's "missing experiments" on weight function quality and sensitivity analysis:** The paper already contains sensitivity analyses for different regressors (Appendix E.4) and weight functions (Appendix E.5), as stated in lines 821–822. While the appendix was stripped by the parser, the paper clearly references these experiments. The critic likely missed these references.

- **Strength Finder's "Practical real-world validation" (supporting strength #3):** "On 541 NSCLC patients... the method produces treatment-specific LPBs that align with established clinical findings." This framing as "validation" is misleading because counterfactual outcomes cannot be validated on observational data. The real data serves as an illustration of the method's applicability, not as validation of its counterfactual guarantees. Kept the adaptiveness pattern as a genuine strength but removed the stronger "validation" framing.

- **Harsh Critic's claim that "The paper's conclusions about clinical decision-making overreach the evidence":** The paper consistently uses hedging language — "indicates the potential" (abstract), "the potential in supporting personalized clinical decision-making" (line 881), "valuable insights into personalized treatment strategies" (lines 84–85). These are measured claims, not overreach. The concern about disentangling factual from counterfactual evaluation remains valid (kept as a major weakness), but the harsh critic's characterization of the paper's conclusions as overreaching is itself overstated.

- **Strength Finder's "LPB optimization for informativeness" as a standalone supporting strength:** While the optimization procedure works, it is a natural extension of the core method (choose τ that maximizes LPB), not a novel contribution in itself. The optimization results are folded into the main experimental validation.

## Novel Insights

The pairing of weighted conformal prediction with the potential outcomes framework for survival analysis reveals a clean structural insight: the counterfactual coverage probability, under ignorability, can be bounded above by an expectation over the observed (uncensored, treated) distribution with a Radon-Nikodym derivative serving as the weight. This transforms a problem that prior work handled only approximately (via PAC bounds) into one solvable with exact finite-sample guarantees — the key move is recognizing that one can work with an upper bound that is itself identifiable and calibratable, rather than attempting direct estimation of the target quantity.

## Suggestions

- Add a paragraph to Section 5.2 explicitly stating: "Coverage on real data is evaluated only for the factual treatment each patient received; cross-treatment LPB comparisons rely on Assumption 3.1 and should be interpreted as illustrative rather than as empirically validated counterfactual evidence." This would resolve the major weakness without requiring new experiments.
- In the synthetic experiments, add one configuration with a moderate violation of ignorability (e.g., an unobserved confounder affecting both treatment assignment and survival) to give readers a sense of how the coverage degrades under assumption violations.
- Explicitly discuss the specific confounding risks in the lung cancer cohort (e.g., whether VMAT patients differ systematically from IMRT patients on unmeasured characteristics) to contextualize the real-data results.

## Score and Decision

**Calibration anchors:**

| Path | Avg Score | Decision | Comparison |
|------|-----------|----------|------------|
| aMXVp1QK2Q | 2.50 | Reject | Conformal survival LPB paper with fundamental methodological flaws and limited novelty. Our paper is far stronger — novel exact coverage guarantee, correct methodology, strong synthetic validation. |
| wYYOdt3f3L | 3.00 | Reject | Counterfactual prediction paper with novel assumption but weak theory and overclaiming. Our paper has much stronger theoretical backing and empirical support. |
| haU96a8YO5 | 3.50 | Reject | Conformal regression with flow matching — novel but had significant issues. Our paper's theoretical depth and empirical coverage results are stronger. |
| mhJ9jO7ue8 | 4.00 | Reject | Double/debiased ML for survival under poor overlap. Solid methodology but narrower scope. Our paper has broader contribution (exact coverage + counterfactual). |
| qG6O3jMkCj | 4.80 | Accept (Poster) | HTE survival benchmark — valuable but a benchmarking paper. Our paper has stronger methodological novelty. |
| aTxnsFFO7t | 5.33 | Accept (Poster) | Federated causal survival with double robustness. Comparable theoretical depth but our paper's exact finite-sample guarantee is a more novel result for conformal prediction. |
| frv3s3AtUD | 6.00 | Accept (Poster) | Survival calibration via ALD with extensive empirical evaluation and theoretical backing. Our paper has weaker real-data validation but stronger theoretical novelty (first exact counterfactual coverage guarantee). |

The paper under review makes a genuine and novel methodological contribution — the first exact marginal coverage guarantee for counterfactual survival prediction. The theoretical development is rigorous and the synthetic validation is convincing. The main weakness is that the real-data presentation does not sufficiently disentangle what it can validate (factual survival prediction) from what it merely illustrates under strong assumptions (counterfactual comparisons). This is addressable with textual revisions and does not undermine the core contribution. Compared against the anchors, the paper is clearly above the rejected borderline papers (2.5–4.0) and sits comfortably in the Accept range, though somewhat below the strongest accepted papers (6.0+) due to the real-data overstatement issue. It is comparable to aTxnsFFO7t (5.33) in having strong theory with minor real-data caveats, but with a more novel conformal prediction result.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Accept</orange>